Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧

路透中文

Jun 26

BUZZ-Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧

6月26日 - ** Capricor Therapeutics（CAPR.O）股价暴跌14%，至26.17美元

** Capricor表示，美国食品药品监督管理局（FDA）将于7月29日召开咨询委员会 (link) 会议，审议其用于治疗杜氏肌营养不良症（一种遗传性疾病）患者心肌病的细胞疗法deramiocel

** B. Riley证券分析师麦迪逊·埃尔-萨阿迪表示，股价的反应反映了与咨询委员会相关的“渐增的监管风险”

** 美国食品药品监督管理局（FDA）去年以缺乏疗效数据为由，拒绝批准 (link) 该药物，并要求提供更多数据

** Capricor公司去年12月表示，在一项晚期临床试验中，与安慰剂相比，deramiocel显著 (link) 减缓了患者肌肉和心脏功能的衰退

** 埃尔-萨阿迪表示，咨询委员会的这一决定“并不令人意外”，重点应放在数据的可靠性上

** 预计美国食品药品监督管理局（FDA）将于8月22日前就该申请作出决定

** 算上本次交易，该股今年以来累计下跌10%

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2646366666"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2646366666\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2646366666?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-26 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646366666","market":"us","top_or_hot":-1,"title":"Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧</title></head><body><p>\n<span>6月26日</span><span> - </span>** Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>（<span>CAPR.O</span>）股价暴跌14%，至26.17美元</p><p>** Capricor表示，<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局（FDA）将于7月29日召开咨询委员会 (link) 会议，审议其用于治疗杜氏肌营养不良症（一种遗传性疾病）患者心肌病的细胞疗法deramiocel</p><p>** <a href=\"https://laohu8.com/S/RILY\">B. Riley</a>证券分析师麦迪逊·埃尔-萨阿迪表示，股价的反应反映了与咨询委员会相关的“渐增的监管风险”</p><p>** 美国食品药品监督管理局（FDA）去年以缺乏疗效数据为由，拒绝批准 (<span>link</span>) 该药物，并要求提供更多数据</p><p>** Capricor公司去年12月表示，在一项晚期临床试验中，与安慰剂相比，deramiocel显著 (<span>link</span>) 减缓了患者肌肉和心脏功能的衰退</p><p>** 埃尔-萨阿迪表示，咨询委员会的这一决定“并不令人意外”，重点应放在数据的可靠性上</p><p>** 预计美国食品药品监督管理局（FDA）将于8月22日前就该申请作出决定</p><p>** 算上本次交易，该股今年以来累计下跌10%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-06-26 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧</title></head><body><p>\n<span>6月26日</span><span> - </span>** Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>（<span>CAPR.O</span>）股价暴跌14%，至26.17美元</p><p>** Capricor表示，<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局（FDA）将于7月29日召开咨询委员会 (link) 会议，审议其用于治疗杜氏肌营养不良症（一种遗传性疾病）患者心肌病的细胞疗法deramiocel</p><p>** <a href=\"https://laohu8.com/S/RILY\">B. Riley</a>证券分析师麦迪逊·埃尔-萨阿迪表示，股价的反应反映了与咨询委员会相关的“渐增的监管风险”</p><p>** 美国食品药品监督管理局（FDA）去年以缺乏疗效数据为由，拒绝批准 (<span>link</span>) 该药物，并要求提供更多数据</p><p>** Capricor公司去年12月表示，在一项晚期临床试验中，与安慰剂相比，deramiocel显著 (<span>link</span>) 减缓了患者肌肉和心脏功能的衰退</p><p>** 埃尔-萨阿迪表示，咨询委员会的这一决定“并不令人意外”，重点应放在数据的可靠性上</p><p>** 预计美国食品药品监督管理局（FDA）将于8月22日前就该申请作出决定</p><p>** 算上本次交易，该股今年以来累计下跌10%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4T42Y0ZU:1","article_id":"2646366666","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646366666","pubTimestamp":1782486159,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧6月26日-** Capricor Therapeutics（CAPR.O）股价暴跌14%，至26.17美元** Capricor表示，美国食品药品监督管理局（FDA）将于7月29日召开咨询委员会 (link) 会议，审议其用于治疗杜氏肌营养不良症（一种遗传性疾病）患者心肌病的细胞疗法d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","CAPR":"Capricor Therapeutics Inc"},"translate_title":"Capricor stock plunges as FDA committee of experts meets on cell therapy for Duchenne muscular dystrophy, adding to market concerns about risk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":0.9},"content_text":"BUZZ-Capricor股价暴跌，因FDA专家委员会就杜氏肌营养不良症细胞疗法召开会议，加剧了市场对风险的担忧\n6月26日 - ** Capricor Therapeutics（CAPR.O）股价暴跌14%，至26.17美元** Capricor表示，美国食品药品监督管理局（FDA）将于7月29日召开咨询委员会 (link) 会议，审议其用于治疗杜氏肌营养不良症（一种遗传性疾病）患者心肌病的细胞疗法deramiocel** B. Riley证券分析师麦迪逊·埃尔-萨阿迪表示，股价的反应反映了与咨询委员会相关的“渐增的监管风险”** 美国食品药品监督管理局（FDA）去年以缺乏疗效数据为由，拒绝批准 (link) 该药物，并要求提供更多数据** Capricor公司去年12月表示，在一项晚期临床试验中，与安慰剂相比，deramiocel显著 (link) 减缓了患者肌肉和心脏功能的衰退** 埃尔-萨阿迪表示，咨询委员会的这一决定“并不令人意外”，重点应放在数据的可靠性上** 预计美国食品药品监督管理局（FDA）将于8月22日前就该申请作出决定** 算上本次交易，该股今年以来累计下跌10%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}